120 Participants Needed

tDCS for Obsessive-Compulsive Disorder

PM
PH
RJ
Overseen ByRyan Jacoby, PhD
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: Massachusetts General Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understand how future treatments can help patients with OCD better control unwanted fear.

Do I have to stop taking my current medications for the trial?

You can continue most psychotropic medications like SSRIs and atypical antipsychotics. However, you must stop using benzodiazepines at least 2 weeks before the study and during the study.

What data supports the idea that tDCS for Obsessive-Compulsive Disorder is an effective treatment?

The available research shows that transcranial direct current stimulation (tDCS) may help reduce symptoms in people with Obsessive-Compulsive Disorder (OCD) who do not respond to other treatments. Studies have reported improvements in OCD symptoms, as well as in depression and anxiety, in patients who are resistant to traditional therapies. However, these findings are based on a limited number of studies with small groups of participants, and more research is needed to confirm these results.12345

What safety data exists for tDCS treatment?

Transcranial Direct Current Stimulation (tDCS) is generally considered safe, with no reports of serious adverse effects or irreversible injury in human trials using conventional protocols (≤40 min, ≤4 milliamperes, ≤7.2 Coulombs) across over 33,200 sessions and 1000 subjects, including vulnerable populations. Adverse events are typically low and transient. However, some caution is advised as there are concerns about potential risks in healthy volunteers.26789

Is tDCS a promising treatment for Obsessive-Compulsive Disorder?

Yes, tDCS is a promising treatment for Obsessive-Compulsive Disorder, especially for patients who do not respond to traditional treatments. It has shown potential in reducing OCD symptoms, as well as related depression and anxiety.123510

Research Team

JC

Joan Camprodon, MD, MPH, PhD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for English-speaking adults with primary OCD causing moderate distress (Y-BOCS score ≥ 16). Participants should be comfortable using a computer. Excluded are those with significant head injuries, metal implants in the head/neck, pacemakers, pregnancy, epilepsy, recent substance abuse, history of mania or psychosis, resistance to multiple OCD treatments or use of benzodiazepines within two weeks.

Inclusion Criteria

Fluent in English, willing to provide informed consent, and willing to comply with the study protocol
My OCD causes significant distress or problems in my life.
Comfortable and capable of using a computer and completing computerized tasks

Exclusion Criteria

Current substance use disorder (within the past 12 months)
My vision problems could affect my participation.
I don't have metal implants, VP shunts, a pacemaker, am not pregnant, and don't have epilepsy.
See 7 more

Treatment Details

Interventions

  • tDCS
Trial OverviewThe study tests whether transcranial Direct Current Stimulation (tDCS) can help people with OCD overcome unwanted fear by altering brain activity. It compares active tDCS against sham (placebo) treatment to see if there's an improvement in managing fear.
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Active tDCS administered during extinction phaseExperimental Treatment1 Intervention
The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
Group II: Active tDCS administered before extinction phaseExperimental Treatment1 Intervention
The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
Group III: Active tDCS administered after extinction phaseExperimental Treatment1 Intervention
The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
Group IV: Sham tDCSPlacebo Group1 Intervention
Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

Foundation for OCD Research

Collaborator

Trials
2
Recruited
480+

Findings from Research

In a study of 32 patients with treatment-resistant obsessive-compulsive disorder (OCD), 28% showed at least a partial response to transcranial direct current stimulation (tDCS) after 10-20 sessions.
Among the responders, 25% had a significant improvement, suggesting that tDCS could be a beneficial treatment option for some individuals who do not respond to traditional therapies.
Transcranial direct current stimulation for treatment-resistant obsessive-compulsive disorder-A large case series.Thamby, A., Seshachala, K., Sharma, L., et al.[2021]
In a study involving 24 patients with Obsessive-Compulsive Disorder (OCD), transcranial Direct Current Stimulation (tDCS) applied to the Left Dorsolateral Prefrontal Cortex (DLPFC) resulted in significant symptom improvement, as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).
The Left DLPFC group showed a mean difference of -6.18 in Y-BOCS scores compared to the sham group, indicating that tDCS may be an effective treatment option for reducing OCD symptoms.
Effect of Transcranial Direct Current Stimulation on Dorsolateral Prefrontal Cortex to Reduce the Symptoms of the Obsessive-Compulsive Disorder.Shafiezadeh, S., Eshghi, M., Dokhaei, Z., et al.[2022]
Transcranial direct current stimulation (tDCS) shows promise as a treatment for patients with treatment-resistant obsessive-compulsive disorder (OCD), with 77 patients in various studies reporting decreased symptoms, including comorbid depression and anxiety.
Current research lacks sham-controlled studies, highlighting the need for more rigorous trials to confirm the efficacy of tDCS and to standardize treatment parameters, as existing studies have methodological limitations.
Transcranial Direct Current Stimulation for Obsessive-Compulsive Disorder: A Systematic Review.Brunelin, J., Mondino, M., Bation, R., et al.[2020]

References

Transcranial direct current stimulation for treatment-resistant obsessive-compulsive disorder-A large case series. [2021]
Effect of Transcranial Direct Current Stimulation on Dorsolateral Prefrontal Cortex to Reduce the Symptoms of the Obsessive-Compulsive Disorder. [2022]
Transcranial Direct Current Stimulation for Obsessive-Compulsive Disorder: A Systematic Review. [2020]
Transcranial direct current stimulation in patients with obsessive compulsive disorder: A randomized controlled trial. [2020]
[Transcranial direct current stimulation (tDCS) for obsessive-compulsive disorder: A new treatment option?] [2020]
Feasibility, acceptability and practicality of transcranial stimulation in obsessive compulsive symptoms (FEATSOCS): A randomised controlled crossover trial. [2023]
Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. [2022]
A Systematic Review on the Acceptability and Tolerability of Transcranial Direct Current Stimulation Treatment in Neuropsychiatry Trials. [2018]
Safety of transcranial direct current stimulation in healthy participants. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Immediate Effects of Transcranial Direct Current Stimulation on Obsession-Induced Anxiety in Refractory Obsessive-Compulsive Disorder: A Pilot Study. [2019]